Optimization and Validation of ELISA for Pre-Clinical Trials of Influenza Vaccine
Апстракт
Testing of every new vaccine involves investigation of its immunogenicity, which is based on monitoring its ability to induce specific antibodies in animals. The fastest and most sensitive method used for this purpose is enzyme-linked immunosorbent assay (ELISA). However, commercial ELISA kits with whole influenza virus antigens are not available on the market, and it is therefore essential to establish an adequate assay for testing influenza virus-specific antibodies. We developed ELISA with whole influenza virus strains for the season 2011/2012 as antigens and validated it by checking its specificity, accuracy, linearity, range, precision, and sensitivity. The results show that we developed high-quality ELISA that can be used to test immunogenicity of newly produced seasonal or pandemic vaccines in mice. The pre-existence of validated ELISA enables shortening the time from the process of vaccine production to its use in patients, which is particularly important in the case of a pande...mic.
Кључне речи:
ELISA / influenza / validation / pandemicИзвор:
Folia Biologica (Czech Republic), 2016, 62, 6, 241-249Издавач:
- Charles Univ Prague, First Faculty Medicine, Prague 6
Финансирање / пројекти:
- Алергени, антитела, ензими и мали физиолошки значајни молекули: дизајн, структура, функција и значај (RS-MESTD-Basic Research (BR or ON)-172049)
Институција/група
TorlakTY - JOUR AU - Mitić, Katarina AU - Muhandes, Lina AU - Minić, Rajna AU - Petrušić, Vladimir AU - Živković, Irena PY - 2016 UR - http://intor.torlakinstitut.com/handle/123456789/464 AB - Testing of every new vaccine involves investigation of its immunogenicity, which is based on monitoring its ability to induce specific antibodies in animals. The fastest and most sensitive method used for this purpose is enzyme-linked immunosorbent assay (ELISA). However, commercial ELISA kits with whole influenza virus antigens are not available on the market, and it is therefore essential to establish an adequate assay for testing influenza virus-specific antibodies. We developed ELISA with whole influenza virus strains for the season 2011/2012 as antigens and validated it by checking its specificity, accuracy, linearity, range, precision, and sensitivity. The results show that we developed high-quality ELISA that can be used to test immunogenicity of newly produced seasonal or pandemic vaccines in mice. The pre-existence of validated ELISA enables shortening the time from the process of vaccine production to its use in patients, which is particularly important in the case of a pandemic. PB - Charles Univ Prague, First Faculty Medicine, Prague 6 T2 - Folia Biologica (Czech Republic) T1 - Optimization and Validation of ELISA for Pre-Clinical Trials of Influenza Vaccine EP - 249 IS - 6 SP - 241 VL - 62 UR - https://hdl.handle.net/21.15107/rcub_intor_464 ER -
@article{ author = "Mitić, Katarina and Muhandes, Lina and Minić, Rajna and Petrušić, Vladimir and Živković, Irena", year = "2016", abstract = "Testing of every new vaccine involves investigation of its immunogenicity, which is based on monitoring its ability to induce specific antibodies in animals. The fastest and most sensitive method used for this purpose is enzyme-linked immunosorbent assay (ELISA). However, commercial ELISA kits with whole influenza virus antigens are not available on the market, and it is therefore essential to establish an adequate assay for testing influenza virus-specific antibodies. We developed ELISA with whole influenza virus strains for the season 2011/2012 as antigens and validated it by checking its specificity, accuracy, linearity, range, precision, and sensitivity. The results show that we developed high-quality ELISA that can be used to test immunogenicity of newly produced seasonal or pandemic vaccines in mice. The pre-existence of validated ELISA enables shortening the time from the process of vaccine production to its use in patients, which is particularly important in the case of a pandemic.", publisher = "Charles Univ Prague, First Faculty Medicine, Prague 6", journal = "Folia Biologica (Czech Republic)", title = "Optimization and Validation of ELISA for Pre-Clinical Trials of Influenza Vaccine", pages = "249-241", number = "6", volume = "62", url = "https://hdl.handle.net/21.15107/rcub_intor_464" }
Mitić, K., Muhandes, L., Minić, R., Petrušić, V.,& Živković, I.. (2016). Optimization and Validation of ELISA for Pre-Clinical Trials of Influenza Vaccine. in Folia Biologica (Czech Republic) Charles Univ Prague, First Faculty Medicine, Prague 6., 62(6), 241-249. https://hdl.handle.net/21.15107/rcub_intor_464
Mitić K, Muhandes L, Minić R, Petrušić V, Živković I. Optimization and Validation of ELISA for Pre-Clinical Trials of Influenza Vaccine. in Folia Biologica (Czech Republic). 2016;62(6):241-249. https://hdl.handle.net/21.15107/rcub_intor_464 .
Mitić, Katarina, Muhandes, Lina, Minić, Rajna, Petrušić, Vladimir, Živković, Irena, "Optimization and Validation of ELISA for Pre-Clinical Trials of Influenza Vaccine" in Folia Biologica (Czech Republic), 62, no. 6 (2016):241-249, https://hdl.handle.net/21.15107/rcub_intor_464 .